Stay updated with breaking news from Amber Salzman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile -
Virtual event today at 2 PM ET featuring this year's 20 Women in Biopharma R&D honorees. Hosted by Endpoints editors Amber Tong and Nicole DeFeudis, including awards presentation and panel discussionLAWRENCE, Kan.--(BUSINESS WIRE)--#awards--Endpoints News announced today its annual Women in Biopharma special report,...
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.